Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial

@article{Tran2013FeasibilityOR,
  title={Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial},
  author={Ben Tran and Andrew M. K. Brown and Philippe B{\'e}dard and Eric Winquist and Glenwood D Goss and Sebastien Hotte and Stephen A. Welch and Hal W. Hirte and Tong Zhang and Lincoln D. Stein and Vincent Ferretti and Stuart N. Watt and Wei Jiao and Karen Ng and Sangeet Ghai and Patricia A. Shaw and Teresa Petrocelli and Thomas J Hudson and Benjamin G. Neel and Nicole Onetto and Lillian L. Siu and John D. McPherson and Suzanne Kamel‐Reid and Janet E. Dancey},
  journal={International Journal of Cancer},
  year={2013},
  volume={132}
}
The successes of targeted drugs with companion predictive biomarkers and the technological advances in gene sequencing have generated enthusiasm for evaluating personalized cancer medicine strategies using genomic profiling. We assessed the feasibility of incorporating real‐time analysis of somatic mutations within exons of 19 genes into patient management. Blood, tumor biopsy and archived tumor samples were collected from 50 patients recruited from four cancer centers. Samples were analyzed… Expand
Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients
TLDR
High concordance to tDNA is shown suggesting that the DST approach may be used as a non-invasive biopsy-free alternative to conventional sequencing using tumor biopsy. Expand
Clinical tumor sequencing: opportunities and challenges for precision cancer medicine.
TLDR
Although whole-genome sequencing offers the most complete strategy for tumor analysis, its present utility in clinical care is limited, and targeted gene capture panels are more commonly employed by academic institutions and commercial vendors for clinical grade cancer genomic testing to assess molecular eligibility for matching therapies. Expand
Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers
TLDR
Although barriers to broader application exist, including the need for wider availability of therapies, IGP in a CLIA-framework is feasible and valuable in selection/prioritisation of anti-cancer therapeutic targets. Expand
Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms
TLDR
The results indicate that the panels enable accurate variant detection despite sequencing from FFPE DNA, and allow mutation detection of core cancer genes including KRAS, BRAF, and EGFR. Expand
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail
TLDR
Targeted high-coverage NGS panels are a highly feasible single-centre technology well-suited to cross-platform validation, enrichment of trials with molecularly defined populations and hypothesis testing early in drug development. Expand
Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer
TLDR
The findings demonstrate that targeted NGS using cfDNA is a feasible approach for rapid and accurate identification of actionable mutations in patients with advanced NSCLC, and may provide a safe and robust alternative approach to tissue biopsy. Expand
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care
TLDR
The need for information and decision tools to support physicians in communicating realistic prospects of benefit and for cautious approaches to the generation of incidental genetic information is suggested. Expand
Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making
TLDR
In the samples analyzed, PCDx significantly outperformed F1 in TAT, and had statistically significant higher clinically relevant actionable targets categorized as CA. Expand
Biology of Human Tumors Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers : A Proof-of-Concept Study
Purpose:Tumor somaticmutation analysis is part of the standardmanagement ofmetastatic lung cancer. However, physicians often have to deal with small biopsies and consequently with challengingExpand
Standardized decision support in next generation sequencing reports of somatic cancer variants
TLDR
A systematic framework for variant annotation and prioritization is described, and a structured molecular pathology report using standardized terminology is proposed in order to best inform oncology clinical practice. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
TLDR
The implementation of a genotyping and validation algorithm that enables robust tumor mutation profiling in the clinical setting and demonstrates the clinical feasibility of high-throughput mutation profiling to query a large panel of “actionable” cancer gene mutations is reported. Expand
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry.
TLDR
A prospective genotyping approach was implemented to characterize the frequency and spectrum of mutations amenable to drug targeting present in urothelial, colorectal, endometrioid, and thyroid carcinomas and in melanoma, demonstrating the diversity and complexity of mutations in druggable targets among the different cancer types. Expand
Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials
TLDR
Development, validation, and implementation of an assay designed to simultaneously detect 43 common somatic point mutations in 6 genes potentially relevant to existing and emerging targeted therapies specifically in melanoma are reported on. Expand
Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
TLDR
The mutations present in advanced cancers can be identified by integrative high-throughput sequencing to enable biomarker-driven clinical trials and, ultimately, treatment and the authors tested this approach by extensively characterizing cancers in several patients and then convening a Sequencing Tumor Board of experts to determine the appropriate treatment. Expand
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
TLDR
It is possible to identify molecular targets in patients' tumors from nine different centers across the United States and in 27% of patients, the MP approach resulted in a longer PFS on an MP-suggested regimen than on the regimen on which the patient had just experienced progression. Expand
Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center Initiative.
TLDR
Preliminary results suggest that in early clinical trials matching patients with targeted drugs based on their molecular profile results in (a) longer TTF compared to their prior therapy and (b) higher rates of response, survival and TTFCompared to those seen in patients treated without molecular matching. Expand
Cancer genomics: technology, discovery, and translation.
  • B. Tran, J. Dancey, +10 authors L. Siu
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
The technology underlying cancer genomics is highlighted and the early results of genome sequencing and the challenges met in the discovery of new genetic aberrations are examined. Expand
Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis
TLDR
It is suggested that late switch in KRAS mutational status could occur more frequently than currently recognized and account for acquired resistance to anti-EGFR therapies. Expand
Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping.
TLDR
Standard sequencing is suboptimal for mutation detection in metastatic and treated lesions even with predissection for tumor enrichment, whereas the Sequenom platform shows intermediate sensitivity but offers significant advantages for broader mutation screening. Expand
PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression
TLDR
This data is clinically important, particularly, for the design of therapies targeting the PI3K/AKT pathway, as it offers confidence that the detection of PIK3CA mutations in the invasive primary tumor will accurately reflect breast cancer biology. Expand
...
1
2
3
...